Skip to main content
. 2015 Dec 4;7(4):3884–3896. doi: 10.18632/oncotarget.6461

Figure 5. Kaplan-Meier analysis of overall survival according to EGFR IHC score in NSCLC patients.

Figure 5

Patients were all treated with gefitinib. The H scores of 100 was chosen as the cutoff point for separating tumors with high or low EGFR expression. The P value for the difference between the two curves was determined by the log-rank test (P = 0.031).